Chemoprevention use after TNBC ‘may be reasonable’

Research indicates that women with triple-negative breast cancer might benefit from low-dose tamoxifen to reduce the risk of recurrent or new primary disease.
Mixed results for tetramethylpyrazine nitrone treatment in ALS

Tetramethylpyrazine nitrone does not slow overall functional decline in patients with amyotrophic lateral sclerosis, but it may help retain grip strength and is well tolerated, suggest study findings.
Quantifying high-risk chromosomal aberrations predicts multiple myeloma prognosis

The presence of two or more high-risk chromosomal aberrations in patients with multiple myeloma is associated with an especially poor outcome throughout the disease course, shows research published in the Journal of Clinical Oncology.
Cancer-related PE death increase shown in the USA

US study findings indicate that the incidence of pulmonary embolism-related death in people with cancer rose significantly between 2011 and 2020 despite an overall reduction in age-adjusted cancer diagnoses and cancer-related deaths over the period.
Larotrectinib discontinuation possible for some paediatric NTRK fusion-positive tumours

Children who respond to larotrectinib therapy for sarcoma with a neurotrophic tyrosine receptor kinase gene fusion may be able to discontinue treatment, indicates research published in the Journal of Clinical Oncology.
Urinary DNA methylation test may improve bladder cancer detection

Measuring levels of urinary DNA methylation may offer a novel and noninvasive test for urothelial cancer, study findings suggest.
Supine hypertension link to CVD events independent of seated hypertension

medwireNews: People with supine hypertension have an increased risk of cardiovascular disease events, irrespective of whether they also have seated hypertension and are taking antihypertensive medication, shows research published in JAMA Cardiology.
OS benefits with perioperative FLOT for resectable oesophageal cancer

Perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel offers better overall survival than preoperative chemoradiotherapy for patients with locally advanced oesopahgeal adenocarcinoma, the ESOPEC trial investigators report.
Adding targeted therapy to TACE improves PFS for unresectable nonmetastatic liver cancer

Progression-free survival findings from two phase 3 clinical trials support the use of targeted therapies in combination with transarterial chemoembolisation for the treatment of patients with unresectable, nonmetastatic hepatocellular carcinoma.
Adjuvant radiation may preserve HRQoL for low-risk breast cancer patients aged 70+

Two-year interim findings from the EUROPA trial indicate that radiotherapy after surgery for low-risk early breast cancer may be better for preserving health-related quality of life for women aged 70 years and older than endocrine therapy.